We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the latest trading day at $71.64, indicating a +1.17% change from the previous session's end. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 1.85%, and the Nasdaq, a tech-heavy index, added 0.2%.
Shares of the HIV and hepatitis C drugmaker have appreciated by 10.18% over the course of the past month, outperforming the Medical sector's gain of 0.71% and the S&P 500's gain of 3.82%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings report is set to go public on August 8, 2024. It is anticipated that the company will report an EPS of $1.58, marking a 17.91% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $6.66 billion, up 0.99% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.73 per share and a revenue of $27.45 billion, representing changes of -44.49% and +1.21%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.9% lower. Gilead Sciences is currently a Zacks Rank #3 (Hold).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 19. This expresses a discount compared to the average Forward P/E of 23.93 of its industry.
We can also see that GILD currently has a PEG ratio of 3.03. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 2.25.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 83, positioning it in the top 33% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
Gilead Sciences (GILD - Free Report) closed the latest trading day at $71.64, indicating a +1.17% change from the previous session's end. This change outpaced the S&P 500's 0.64% gain on the day. Meanwhile, the Dow gained 1.85%, and the Nasdaq, a tech-heavy index, added 0.2%.
Shares of the HIV and hepatitis C drugmaker have appreciated by 10.18% over the course of the past month, outperforming the Medical sector's gain of 0.71% and the S&P 500's gain of 3.82%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings report is set to go public on August 8, 2024. It is anticipated that the company will report an EPS of $1.58, marking a 17.91% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $6.66 billion, up 0.99% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.73 per share and a revenue of $27.45 billion, representing changes of -44.49% and +1.21%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.9% lower. Gilead Sciences is currently a Zacks Rank #3 (Hold).
Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 19. This expresses a discount compared to the average Forward P/E of 23.93 of its industry.
We can also see that GILD currently has a PEG ratio of 3.03. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 2.25.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 83, positioning it in the top 33% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.